Neuland Laboratories Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/utopt0uw3nio1gxsab7fscgn.pdf

Key Takeaways


Margin & Product Mix

Davuluri: "What I can assure you is that the gross margin that you've seen in this quarter is more of an outlier or an aberration for multiple reasons that it is not a steady gross margin going forward."

CMS Ramp-Up & Capacity

Davuluri: "I think maybe we should see as reaching full production soon, not just for the Unit 3 new facility, but for the other CDMO molecule as well. But I think there are too many unknowns that we are dealing with."

Inventory Build


Pipeline & Commercial Portfolio


Peptides: The Next Growth Vector

Davuluri: "When you have a good modern R&D setup for peptides, in our new campus in Genome Valley. And then you combine that with the newly created large-scale peptide manufacturing capacity, then we would have a configuration, which would probably not be matched by many Indian CDMOs."

Trade Policy & External Environment

Davuluri: "There seems to be a continued intent for the U.S. to secure API manufacturing in the U.S. And that's something that we'll have to still wait and watch. I think the U.S. India trade deal does not really alleviate that potential concern."

Long-Term Strategic Ambition

Davuluri: "I think if you look at 2026 to 2036 I think there is a potential for a business like this to grow at 20-plus CAGR, but that requires I think, a sequence of right plans to fall in place."

Guidance & Commitments

CommitmentSpecificsTimeline
CMS capacity ramp-upExpanded CMS capacity to pick up meaningfullyOne to two quarters
Paliperidone resolutionOperational issues at customer end to resolveNext financial year (FY27), not next quarter
Peptide facility commissioningLarge-scale peptide manufacturing facility readyJuly
Peptide commercial arrangementSecure at least 1 commercial manufacturing arrangement for a peptide NCEFY27 (ideal target)
Growth deliveryGrowth preordained by existing products; ramp-ups to show business potentialNext 2-3 quarters through FY27
Gross margin normalizationThis quarter is an outlier; prior 2-3 quarters are better representationGoing forward (no date)

Key Metrics

MetricQ3 FY26
Total income₹447.8 cr, +11.4% YoY vs ₹401.9 cr
Commercial CMS revenue shareOver 50% of total revenue
Gross marginAn outlier/aberration this quarter, not a steady gross margin going forward; product mix was the largest factor
EBITDA margin (FY24 reference)~30% in FY24, business capable of 30% and higher
Net debtNegative ₹202.6 cr (net cash position)
Capex (9M FY26)₹254 cr cash outflow
Free cash flow (FY26 to date)Negative ₹9.2 cr, restricted by substantial customer advances
Inventory₹548 cr, up from ₹386 cr; inventory days at 124 days on current sales basis, up from 94 days in FY25
CMS pipeline valueSeveral multi-hundred crore molecules in pipeline; first commercial CMS molecule was ~₹30 cr
Growth outlook20%+ CAGR potential from 2026 to 2036; next 2–3 years growth preordained by existing products
Peptide capacityNew large-scale peptide manufacturing capacity expected ready for commissioning in July (FY27)
New R&D campusBoard approved shifting R&D to a new campus in Genome Valley
Unit 3 capacity expansionCompleted; ramp-up started in Q3, expected to reach full production over next 1–2 quarters
New CMS molecule commercializationCommercialized; some shipments at tail end of Q3, majority of ramp-up still ahead
Paliperidone shipment delayOperational issues at customer end caused delay; resolution expected next financial year